Theron Pharmaceuticals is focused on developing a long-acting M3 muscarinic antagonist (LAMA) aimed at enhancing the treatment of chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD) and severe asthma. Their lead candidate, TRN-157, is designed to offer superior efficacy and safety compared to existing treatments, such as tiotropium, which is currently the only approved LAMA. TRN-157 is being developed with excellent physicochemical properties that allow for compatibility with various inhalation devices, including dry powder inhalers (DPI), metered-dose inhalers (MDI), and nebulizers. This flexibility is crucial for creating effective combination therapies that can improve patient outcomes and simplify disease management.

The company’s drug discovery efforts are supported by a team with extensive experience in the pharmaceutical industry, having a proven track record of developing new molecular entities. Theron’s approach includes the potential for co-formulation with other therapeutic agents, such as long-acting beta agonists (LABA) and inhaled corticosteroids (IC), which could lead to innovative once-a-day combination therapies. The company is currently in advanced IND-enabling studies for TRN-157 and is actively seeking pharmaceutical partners to facilitate the clinical-stage development of their product, indicating a strategic focus on collaboration to enhance their market presence and therapeutic offerings.

United States

Theron Pharmaceuticals is a privately held biotechnology company developing a best-in-class, long acting M3 muscarinic antagonist (LAMA) for the improved treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma. The goal of Theron's LAMA program is to develop a once-daily inhaled bronchodilator that possesses the adequate physicochemical properties for broad inhalation device flexibility (DPI, MDI and nebulizer) in addition to excellent co-formulation compatibility for use in multi-drug combination products.

Theron Pharmaceuticals

Company Details